cart Shopping Cart    You have 0 items   
Want to become a member?
Sign up here!
media releases
news archive
past events

News & Events

Allergy Awareness Week 2022

8 - 14 May

An enthusiastic team of Allergy New Zealand volunteers have been working hard to present an excellent pack of allergy resources for our early childhood centres, schools and Kura this year.  It is specifically designed for teachers and kura tātou to help them raise awareness and knowledge of allergies, but many of these resources and links will be also be a huge help to parents and whānau.  Please enjoy and share these allergy resources with friends, colleagues, whānau, caregivers and tamariki, to help us all raise awareness and to be inclusive of people living with allergies. "Allergy care and prevention is simple if you know how".

To view the resources, visit: HERE

AAW 2022 - Hero shot-145-47-844-60-538-506


Free EpiPen® Campaign Returns in Response to Overwhelming Demand

February 2022

Allergy New Zealand and Pub Charity have relaunched the successful FundaPen campaign to deliver 3,355 free lifesaving EpiPen® auto-injectors to patients who have a doctor-diagnosed allergy and are at risk of anaphylaxis. 

The FundaPen2 initiative follows the first campaign in 2019, which saw nearly 3,000 New Zealanders receive a free EpiPen® (adrenaline autoinjector).

Allergy New Zealand Chief Executive Mark Dixon says, “The lifechanging campaign was wholeheartedly supported by medical professionals and members of the allergy community, who have been calling for a repeat of it, since it came to an end in 2020”.

Read more, HERE
 


FundaPen™ finishes after 2,875 New Zealanders receive Free EpiPen® 

31 July 2020

FundaPen - a national success! 

Thanks to the $300,000 donation from Pub Charity last year, a total of 2875 free Epipens® have been distributed across New Zealand. The last Fundapen™ provided by this donation was distributed at the end of July - just 9 months after the initiative launched.

We are very grateful for Pub Charity's donation and the support it has provided to people with allergies at risk of anaphylaxis.  

Special thanks also goes to the thousands of General Practice teams, Clinicians, Health Professionals and AllergyPharmacy.co.nz who supported this unique opportunity.  

Moving forward, normal prescriber protocols will apply and patients will be required to pay for their own Epipens®. 

Unfortunately, we have no further funding available to continue this initiative.

We invite PHARMAC, or other potential supporters, to work alongside Allergy New Zealand to help fund this life-saving medicine. For further information, contact allergy@allergy.org.nz


 

Banning foods in schools not the solution: Allergy Advocate 

Click here to read the full article:


 

media realeases allergy nz

Media releases

news archive

News archive

past events

Past events

Media enquires

Mark Dixon
+64 21 623 363
ceo@allergy.org.nz


 

Free EpiPen® Campaign Returns in Response to Overwhelming Demand
 

February 2022

Allergy New Zealand and Pub Charity have relaunched the successful FundaPen campaign to deliver 3,355 free lifesaving EpiPen® auto-injectors to patients who have a doctor-diagnosed allergy and are at risk of anaphylaxis. 

The FundaPen2 initiative follows the first campaign in 2019, which saw nearly 3,000 New Zealanders receive a free EpiPen® (adrenaline autoinjector).

Allergy New Zealand Chief Executive Mark Dixon says, “The lifechanging campaign was wholeheartedly supported by medical professionals and members of the allergy community, who have been calling for a repeat of it, since it came to an end in 2020”.

Read more, HERE
 


 

FundaPen™ finishes after 2,875 New Zealanders receive Free EpiPen® 

31 July 2020

FundaPen - a national success! 

Thanks to the $300,000 donation from Pub Charity last year, a total of 2875 free Epipens® have been distributed across New Zealand. The last Fundapen™ provided by this donation was distributed at the end of July - just 9 months after the initiative launched.

We are very grateful for Pub Charity's donation and the support it has provided to people with allergies at risk of anaphylaxis.  

Special thanks also goes to the thousands of General Practice teams, Clinicians, Health Professionals and AllergyPharmacy.co.nz who supported this unique opportunity.  

Moving forward, normal prescriber protocols will apply and patients will be required to pay for their own Epipens®. 

Unfortunately, we have no further funding available to continue this initiative.

We invite PHARMAC, or other potential supporters, to work alongside Allergy New Zealand to help fund this life-saving medicine. For further information, contact allergy@allergy.org.nz


Allergy Awareness Week, 2020: 10 - 16 May - CANCELLED

Due to continuing COVID-19 uncertainty we need to focus all our resources on advocating and supporting our allergy community through these unprecedented times.

Our continuous efforts to raise allergy awareness continues but we will not have a dedicated week to raise awareness in 2020. We know this will be disappointing news for most of you, especially our younger members. (Please remember all our online resources developed by our wonderful National Volunteer Network are free and can be printed & downloaded here)

 

We wish to thank all of you for your continued support. We are here to support all our members and followers. Please email us on allergy@allergy.org.nz, send us a private message through Facebook or call our support line 0800 34 0800 to speak with our team.

We plan to make up for it next year - 2021 - when we hope to have put this current crisis behind us.


EpiPen Junior supply issue

IMPORTANT NOTIFICATION re: EpiPen® Jr 150mcg Adrenaline (epinephrine) Auto-Injector

We have been advised by Mylan NZ that the supply of EpiPen® Jr 150mcg adrenaline (epinephrine) auto-injectors has been delayed. This means that there is a shortage of EpiPen® Jr in New Zealand. We will update this notice as more information becomes available, including when normal supply is expected to resume. Please note that the supply of EpiPen® 300mcg adrenaline (epinephrine) auto-injectors is NOT affected.

Process for obtaining an EpiPen® Jr 150mcg Adrenaline (epinephrine) Auto-Injector

Mylan, the supplier of EpiPen® Jr in New Zealand, has set up the following process to ensure those at risk of a potentially life-threatening allergic reaction (anaphylaxis), have access to the emergency treatment they may need:

  • Patients requiring an EpiPen® Jr are being directed to contact their local pharmacy.
  • Pharmacies can then contact the Mylan Consumer Freephone on 0800 168 169 or info@mylan.co.nz to obtain instructions on how to access the emergency supply.
  • During the current supply constraint, only ONE EpiPen® Jr should be dispensed to each patient.

The Australasian Society of Clinical Immunology and Allergy (ASCIA) has provided further advice on their website:  https://www.allergy.org.au/about-ascia/info-updates/epipen-jr-supply-update

Can a higher dose of adrenaline be given to a young child if no EpiPen ®Jr is available?

In Australia and New Zealand, there are currently two doses of adrenaline autoinjectors available:

  • EpiPen® (0.3mg) is usually prescribed for adults and children, weighing over 20 kg.
  • EpiPen®Jr (0.15mg) is usually prescribed for children, weighing 7.5 -20 kg.

Whilst 10-20kg was the previous weight guide for a 0.15mg adrenaline auto-injector, a 0.15mg device may now also be prescribed for an infant weighing 7.5-10kg by health professionals who have made a considered assessment. Use of a 0.15mg device for treatment of infants weighing 7.5kg or more poses less risk, particularly when used without medical training, than use of an adrenaline ampoule and syringe.

A general guide to adrenaline auto-injector doses

  • Children under 7.5kg are not usually prescribed an adrenaline auto-injector. If anaphylaxis is suspected, only a 0.15mg device should be given. Higher dose adrenaline auto-injectors should NOT be administered to children under 7.5kg.
  • In children weighing 7.5- 20kg, a 0.15mg adrenaline auto-injector should be used. However, if only a 0.3mg device is available, this should be used in preference to not using one at all.

ASCIA Guidelines for adrenaline auto-injector prescription are available at allergy.org.au/hp/anaphylaxis/adrenaline-autoinjector-prescription

 


 

Banning foods in schools not the solution: Allergy Advocate 

Click here to read the full article:


Mid winter brings early onset hayfever to Canterbury 
Newshub sat down with Allergy New Zealand CEO Mark Dixon to discuss the mid-winter rise of pollen in New Zealand, with Cantabrians noticing allergy season settling in earlier than usual this year.

Click here for the full news broadcast.


 

media realeases allergy nz

Media releases

news archive

News archive

past events

Past events

Media enquires

Mark Dixon
+64 21 623 363
ceo@allergy.org.nz


 

Free EpiPen® Campaign Returns in Response to Overwhelming Demand
 

February 2022

Allergy New Zealand and Pub Charity have relaunched the successful FundaPen campaign to deliver 3,355 free lifesaving EpiPen® auto-injectors to patients who have a doctor-diagnosed allergy and are at risk of anaphylaxis. 

The FundaPen2 initiative follows the first campaign in 2019, which saw nearly 3,000 New Zealanders receive a free EpiPen® (adrenaline autoinjector).

Allergy New Zealand Chief Executive Mark Dixon says, “The lifechanging campaign was wholeheartedly supported by medical professionals and members of the allergy community, who have been calling for a repeat of it, since it came to an end in 2020”.

Read more, HERE
 


 

FundaPen™ finishes after 2,875 New Zealanders receive Free EpiPen® 

31 July 2020

FundaPen - a national success! 

Thanks to the $300,000 donation from Pub Charity last year, a total of 2875 free Epipens® have been distributed across New Zealand. The last Fundapen™ provided by this donation was distributed at the end of July - just 9 months after the initiative launched.

We are very grateful for Pub Charity's donation and the support it has provided to people with allergies at risk of anaphylaxis.  

Special thanks also goes to the thousands of General Practice teams, Clinicians, Health Professionals and AllergyPharmacy.co.nz who supported this unique opportunity.  

Moving forward, normal prescriber protocols will apply and patients will be required to pay for their own Epipens®. 

Unfortunately, we have no further funding available to continue this initiative.

We invite PHARMAC, or other potential supporters, to work alongside Allergy New Zealand to help fund this life-saving medicine. For further information, contact allergy@allergy.org.nz


Allergy Awareness Week, 2020: 10 - 16 May - CANCELLED

Due to continuing COVID-19 uncertainty we need to focus all our resources on advocating and supporting our allergy community through these unprecedented times.

Our continuous efforts to raise allergy awareness continues but we will not have a dedicated week to raise awareness in 2020. We know this will be disappointing news for most of you, especially our younger members. (Please remember all our online resources developed by our wonderful National Volunteer Network are free and can be printed & downloaded here)

 

We wish to thank all of you for your continued support. We are here to support all our members and followers. Please email us on allergy@allergy.org.nz, send us a private message through Facebook or call our support line 0800 34 0800 to speak with our team.

We plan to make up for it next year - 2021 - when we hope to have put this current crisis behind us.


EpiPen Junior supply issue

IMPORTANT NOTIFICATION re: EpiPen® Jr 150mcg Adrenaline (epinephrine) Auto-Injector

We have been advised by Mylan NZ that the supply of EpiPen® Jr 150mcg adrenaline (epinephrine) auto-injectors has been delayed. This means that there is a shortage of EpiPen® Jr in New Zealand. We will update this notice as more information becomes available, including when normal supply is expected to resume. Please note that the supply of EpiPen® 300mcg adrenaline (epinephrine) auto-injectors is NOT affected.

Process for obtaining an EpiPen® Jr 150mcg Adrenaline (epinephrine) Auto-Injector

Mylan, the supplier of EpiPen® Jr in New Zealand, has set up the following process to ensure those at risk of a potentially life-threatening allergic reaction (anaphylaxis), have access to the emergency treatment they may need:

  • Patients requiring an EpiPen® Jr are being directed to contact their local pharmacy.
  • Pharmacies can then contact the Mylan Consumer Freephone on 0800 168 169 or info@mylan.co.nz to obtain instructions on how to access the emergency supply.
  • During the current supply constraint, only ONE EpiPen® Jr should be dispensed to each patient.

The Australasian Society of Clinical Immunology and Allergy (ASCIA) has provided further advice on their website:  https://www.allergy.org.au/about-ascia/info-updates/epipen-jr-supply-update

Can a higher dose of adrenaline be given to a young child if no EpiPen ®Jr is available?

In Australia and New Zealand, there are currently two doses of adrenaline autoinjectors available:

  • EpiPen® (0.3mg) is usually prescribed for adults and children, weighing over 20 kg.
  • EpiPen®Jr (0.15mg) is usually prescribed for children, weighing 7.5 -20 kg.

Whilst 10-20kg was the previous weight guide for a 0.15mg adrenaline auto-injector, a 0.15mg device may now also be prescribed for an infant weighing 7.5-10kg by health professionals who have made a considered assessment. Use of a 0.15mg device for treatment of infants weighing 7.5kg or more poses less risk, particularly when used without medical training, than use of an adrenaline ampoule and syringe.

A general guide to adrenaline auto-injector doses

  • Children under 7.5kg are not usually prescribed an adrenaline auto-injector. If anaphylaxis is suspected, only a 0.15mg device should be given. Higher dose adrenaline auto-injectors should NOT be administered to children under 7.5kg.
  • In children weighing 7.5- 20kg, a 0.15mg adrenaline auto-injector should be used. However, if only a 0.3mg device is available, this should be used in preference to not using one at all.

ASCIA Guidelines for adrenaline auto-injector prescription are available at allergy.org.au/hp/anaphylaxis/adrenaline-autoinjector-prescription

 


 

Banning foods in schools not the solution: Allergy Advocate 

Click here to read the full article:


Mid winter brings early onset hayfever to Canterbury 
Newshub sat down with Allergy New Zealand CEO Mark Dixon to discuss the mid-winter rise of pollen in New Zealand, with Cantabrians noticing allergy season settling in earlier than usual this year.

Click here for the full news broadcast.


 

media realeases allergy nz

Media releases

news archive

News archive

past events

Past events

Media enquires

Mark Dixon
+64 21 623 363
ceo@allergy.org.nz